World J Breast Cancer Res | Volume 4, Issue 1 | Research Article | Open Access

Laser Ablation of Multifocal Breast Carcinoma: Assessing Viability for Patients not Accepting Surgery

Rusy Bhalla1*, Seemantini Bhalla1, Duleep Bhonsale2, Ashish Kapadia2 and Dilip Pawar3

1Department of Oncology, Orchid Center For Laser Surgery, India
2Department of Radiology, Orchid Center For Laser Surgery, India
3Department of Statistics and Epidemiology, Orchid Center For Laser Surgery, India

*Correspondance to: Rusy Bhalla 

Fulltext PDF

Abstract

Breast carcinoma is a major public health problem in India and world. It is the no 1 cause of cancer in women in India. The overall 5 year survival rate in western countries is over 90%. In India it drops to 40% to 60%. The various factors responsible for this include unacceptability of many women for mutilation of their breasts. Breasts being a very important feminine cosmetic benchmark. Laser ablation of breast tumors is now a USFDA and CE approved procedure. The aim of this observational study was to observe completion of tumour ablation by intralesional laser ablation. The Ablation was performed as a single procedure in 10 women over a 7 year period. All women who consented to the procedure were in stage 3 with multifocal and/or multilocational disease. As such they were not candidates for Breast conservation surgery. Results: All patients showed a complete necrosis of the tumour on a follow up of 2 to 7 years. The findings were confirmed on serial PET scans after 6 months and 2 years. Conclusion: Laser Ablation is a viable procedure for patients unwilling for mastectomy in stage 3 breast cancer. The skill sets required for the procedure are new and surgeons will have to be trained for the procedure.

Keywords:

Breast cancer; Stage 3 breast cancer; Laser ablation; Breast conservation surgery

Citation:

Bhalla R, Bhalla S, Bhonsale D, Kapadia A, Pawar D. Laser Ablation of Multifocal Breast Carcinoma: Assessing Viability for Patients not Accepting Surgery. World J Breast Cancer Res. 2021; 4(1): 1019..

Subscribe to Our Newsletter